Morgan Bayer

Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.

EG-70 is an experimental intravesical immunotherapy that does not involve viruses or integration. It aims to eliminate tumors by triggering coordinated innate and adaptive immune reactions specifically within the bladder.

“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.